



Express Mail No.: **EV 452 774 090 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Taylor *et al.*

Confirmation No.: 4486

Application No.: 10/016,763

Group Art Unit: 1648

Filed: October 26, 2001

Examiner: Hankyel Park

For: ANTIGEN-BASED HETEROPOLYMERS
AND METHOD FOR TREATING
AUTOIMMUNE DISEASES USING THE
SAME

Attorney Docket No.: 9426-059

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references B01 and C01-C20, listed on the attached "List of References Cited by Applicant."

References B01 and C01-C20 on the attached List of References Cited by Applicant were cited by or submitted to the Patent and Trademark Office in the prosecution history of patent application Serial No. 08/202,572, filed February 28, 1994, to which the present application claims priority under the provisions of 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of application Serial No. 08/202,572, filed February 28, 1994 for copies of the references cited therein.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

A fee of \$180.00 is believed to be due. Please charge any required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: December 23, 2004

Margaret B. Brivanlou 40,922
Margaret B. Brivanlou (Reg. No.)

William J. Thomann 40,203
By: William J. Thomann (Reg. No.)

JONES DAY

222 East 41st Street

New York, New York 10017-6702

(212) 326-3939


Express Mail No.: **EV 452 774 090 US**

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 9426-059	APPLICATION NO. 10/016,763
	APPLICANT Taylor et al.	
	FILING DATE October 26, 2001	GROUP 1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A01						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
B01	WO 92/05801	4/16/92	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Brown et al., 1988, Clonotypic analysis of the antibody response to the acetylcholine receptor in experimental autoimmune myasthenia gravis. J Neuroimmunol. 19(3):205-22 (Abstract only)
C02	Edberg et al., 1987, Quantitative analysis of the binding of soluble complement-fixing antibody/dsDNA immune complexes to CR1 on human red cross cells. J Immunology. 139(11) 3739-3747
C03	Emlen et al., 1990, A new ELISA for the detection of double-stranded DNA antibodies. J Immunol Methods. 132(1):91-101
C04	Euler et al., 1994, Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum. 37(12):1784-94
C05	Falanga et al., 1987, Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol. 123(3):350-3 (Abstract only)
C06	Ferguson et al., 1995, Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. Arthritis Rheum. 38(2):190-200
C07	Ferguson et al., 1995, Arthritis and Rheumatism 38:190-200, <u>Medline Database Abstract only</u>
C08	Harris et al., 1988, Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis. 157(1):23-31
C09	Karpovsky et al., 1984, Production of target-specific effector cells using heterocross-linked aggregates containing anti-target cell and anti-Fc receptor antibodies. J. Exp. Med. 160, 1686-1697
C10	Kimberly et al., 1989, In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J Clin Invest. 84(3):962-70
C11	Liszewski et al., 1993, "The Complement System" in <i>Fundamental Immunology</i> , William E. Paul, Ed., Raven Press Ltd., New York
C12	Mannucci et al., 1981, Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. Blood. 57(1):25-31 (Abstract only)
C13	Meilof et al., 1990, The detection of anti-Ro/SS-A and anti-La/SS-B antibodies. A comparison of counterimmunoelectrophoresis with immunoblot, ELISA, and RNA-precipitation assays. J Immunol Methods. 133(2):215-26
C14	Morel et al., 1987, Increased binding of anti-acetylcholine receptor antibodies to thymic antigen in patients with myasthenia gravis and other autoimmune diseases, as compared to those with myasthenia gravis alone. J Neuroimmunol. 14(2):221-6 (Abstract only)

O I P E DEC 13 2004	C15	Sutjita et al., 1989, A common anti-cardiolipin antibody idotype in autoimmune disease: identification using a mouse monoclonal antibody directed against a naturally-occurring anti-phospholipid antibody. Clin Exp Immunol. 75(2):211-6 (Abstract only)
E. TRADE	C16	Taylor et al., 1991, Complement-opsonized IgG antibody/dsDNA immune complexes bind to CR1 clusters on isolated human erythrocytes. Clin Immunol Immunopathol. 61(2 Pt 1):143-60
O I P E DEC 23 2004	C17	Taylor et al., 1992, In vivo binding and clearance of circulating antigen by bispecific heteropolymer-mediated binding to primate erythrocyte complement receptor. J Immunol. 148(8):2462-8
O I P E DEC 23 2004	C18	Taylor et al., 1991, Clinical Immunology and Immunopathology 61:143-160, <u>Medline Database Abstract only</u>
PATENT & TRADEMARK OFFICE	C19	Taylor et al., 1997, Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 mAbs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model. Clin Immunol Immunopathol. 82(1):49-59
	C20	Titus et al., 1987, Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunology. 139, 3153-3158.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.